Navigation Links
Rempex Announces Series B Financing of Up to $67.5 Million
Date:11/9/2011

SAN DIEGO, Nov. 9, 2011 /PRNewswire/ -- Rempex Pharmaceuticals, Inc. today announced that it has completed the initial closing of a Series B financing.  New investors Frazier Healthcare Ventures and Vivo Ventures joined existing investors SV Life Sciences, OrbiMed Advisors and Adams Street Partners in committing to a total of $67.5 million for this round.  This financing, together with a previous Series A round, brings the total financing commitment for Rempex to $76 million since the company's founding in June 2011.

Rempex is focused on developing internally discovered new treatments for resistant gram-negative infections.  The company expects to file a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for its first product candidate in the second half of 2012 and an Investigational New Drug Application (IND) with the FDA for its second product candidate in the first quarter of 2012.

"We are very pleased to have been able to attract such a strong group of experienced healthcare investors," stated Daniel Burgess, President and Chief Executive Officer of Rempex.  "This financing gives us the resources to rapidly advance our development programs towards commercialization at a time when the need for new treatments for resistant gram-negative infections has become critical."

About Rempex Pharmaceuticals

Rempex Pharmaceuticals, Inc. is a biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company was founded to acquire all the assets, including financial and human resources, not associated with Aeroquin™ from Mpex Pharmaceuticals, Inc.  Aptalis Holdings Inc. acquired Mpex and its lead product candidate, Aeroquin™, earlier this year.  Company website: www.rempexpharma.com


'/>"/>
SOURCE Rempex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Amylin Pharmaceuticals Announces Date and Time Change to Previously Announced Presentation at the Credit Suisse 2011 Healthcare Conference
2. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
3. China Sky One Medical Announces Third Quarter 2011 Results
4. China Information Technology, Inc. Announces Third Quarter 2011 Results
5. Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator
6. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
7. K-V Pharmaceutical Announces Updated Makena® Performance Metrics
8. MedBox Announces Ticker Symbol Change
9. SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence
10. ECRI Institute Announces its Top 10 Health Technology Hazards for 2012
11. Echo Therapeutics Announces Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Glades Drugs, an independent ... is proud to announce its expansion into a new corporate ... will feature an 8,000-square-foot office space and state of the ... applications for 100 open positions for the new facility. ... Lantana Road will serve as the chain,s corporate headquarters and ...
(Date:8/20/2014)... 2014 Trovagene, Inc. (NASDAQ:   TROV), a ... from two clinical studies will be presented at the ... diagnostic test for the detection of high risk strains ... to take place in Seattle ... Additionally, a new U.S. patent was issued earlier this ...
(Date:8/20/2014)... Texas , Aug. 20, 2014  Quantum ... five diverse sets of patent families from Bayer Technology ... innovation driver for Bayer AG of Leverkusen, ... patents acquired provide broad intellectual property protection for ... economical high-volume quantum dot (QD) manufacturing. In addition, ...
Breaking Medicine Technology:Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4
(Date:8/20/2014)... 20, 2014 According to a ... "Multiplexed Diagnostics Market (Technologies: Very High, High, Medium, ... Disease Diagnosis, Oncology, Autoimmune Diseases, Cardiac, Allergies and ... Trends and Forecast, 2013 - 2019", the global ... billion in 2012 and is expected to grow ...
(Date:8/20/2014)... A survey of U.S. veterans receiving mental health services ... also significant room for improvement among all areas studied. ... 2009, found that patients with a substance use disorder ... health services. Those with substance abuse problems also were ... to them or respected their decisions. , The findings, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 IQ Formulations ... was named to the Inc. 500 , distinguishing it ... United States. IQ Formulations not only made the list, but ... 5,486 percent over the past three years. It also ranked ... state of Florida and the second fastest growing company in ...
(Date:8/20/2014)... San Mateo, CA (PRWEB) August 20, 2014 ... their newest product—the Really Little Green Pouch —to ... easier to feed babies and toddlers homemade foods. ... says Little Green Pouch co-founder Maggie Crawford. She ... their kids, to limit exposure to things like pesticides ...
(Date:8/20/2014)... News) -- Taking the widely used antibiotic ... heart-related causes, a new study suggests. Because millions ... require urgent confirmation, said the Danish researchers behind the ... small and that guidelines for the use of the ... available. One heart expert wasn,t surprised by the ...
Breaking Medicine News(10 mins):Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Survey finds veterans generally satisfied with mental health care 2Health News:Leading Health Supplement Company IQ Formulations Among Inc. Magazine’s Top 50 Fastest Growing Private Companies in the United States 2Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2Health News:Antibiotic Might Raise Heart Risks for Some 2
... most populous city in Australia, with a population of over ... it is also the state capital of New South Wales. ... of the world in energy conservation, in the fight against ... to many areas for an hour. ,Lights were ...
... parties along with activists and film personalities have expressed ... and have vowed to fight it. ,Around ... malnutrition and half of them may die in the ... of Citizen Alliance, who are visiting the villages in ...
... Dana-Farber Cancer Institute have shown in a laboratory study ... counteracts// the damage caused by a form of muscular ... of Genes and Development, the researchers demonstrated that manipulating ... the muscles of mice with Duchenne muscular dystrophy, slowing ...
... at The University of Manchester have discovered that arthritis ... is processed in the //parts of the brain concerned ... Dr Bhavna Kulkarni has captured the first images of ... tomography (PET) scanners based at the Christie Hospital. ...
... till it is six months old could cut the ... ,The Human Immunodeficiency Virus (HIV) is a life-threatening ... to fail. ,Hoosen Coovadia and other researchers ... at the University of KwaZulu-Natal, South Africa, compared solely ...
... pharmaceutical giant, has agreed to stop selling Zelnorm, a ... chances of heart attack and stroke. , ,Officials of ... advised the firm to pull the drug out of the ... its patent application for a cancer drug by Indian authorities. ...
Cached Medicine News:Health News:MPs Vow to Fight Malnutrition in Madhya Pradesh 2Health News:Switching Genes to Overdrive Improves Muscular Dystrophy Symptoms in Mice 2Health News:Arthritis Pain Processed in Brain’s 'fear Zone,' First PET Scans Revea 2Health News:Breastfeeding Could Cut HIV Risk to Babies 2Health News:Constipation Drug Linked to Heart Attack Pulled Out 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: